



**Pascale RICHETTA**

**Executive Vice President  
Head of Bone Patient Value Unit**

Joined UCB in February 2016

Pascale Richetta joins UCB with over 20 years of experience in the pharma and biotech industry. She has acquired impressive commercial experience managing both traditional pharmaceuticals and complex biologics. Her experience and knowledge of markets around the world is key to helping UCB prepare for future product launches.

Trained as a medical doctor (MD), Pascale Richetta leads UCB's Bone Patient Value Unit. One of her main missions is to take UCB's investigational osteoporosis drug *romosozumab* through the next steps in its development and prepare for its potential launch upon approval. She is a member of the Executive Committee.

**Key positions**

Prior to UCB, Pascale held the following positions:

- |           |   |
|-----------|---|
| 2013-2016 | <b>AbbVie</b><br>Vice President, Western Europe and Canada<br>In charge of a multi-billion specialty care portfolio including key biologic products<br>Covering 19 affiliates and over 3000 staff |
| 2004-2013 | <b>Abbott:</b><br>Vice President, Western Europe and Canada   |
| 1994-2004 | <b>GSK</b><br>Operations Director in France and Europe in charge of the Central Nervous System franchise  |
| 1990-1994 | <b>Ipsen</b><br>Marketing Manager Tanakan®, France  |

1987-1990      **Servier**  
Product Manager, Stablon®, France

### Education

1985              University of Poitiers, France  
M.D.

### Prior trade association engagement

**EFPIA**        :      Vice Chair of the Executive Committee, member of the Board

**EBE**         :      Member of the Board

**EuropaBIO** :      Member of the Board